Skip to content
ClinCalc Pro
Menu
Haemostatic / Tissue Adhesive (Biological — Human Plasma-Derived)

Fibrin Glue (Tissue Adhesive — Burns/Plastics)

Brand names: Tisseel, Artiss, Evicel, Quixil

A two-component biological tissue adhesive of fibrinogen and thrombin used in burns and plastics to secure skin grafts, seal raw surfaces and provide local haemostasis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Mixing the components reproduces the final stage of the clotting cascade, with thrombin converting fibrinogen to a fibrin clot that adheres tissues and stops bleeding.

Prescribing in practice

  • It must never be injected intravascularly, as intravascular application can cause life-threatening thromboembolism.
  • Being derived from pooled human plasma, it carries a theoretical infection-transmission risk and may contain components contraindicated in known hypersensitivity, including to aprotinin where present.
  • Apply only to the tissue surface as a thin layer per the product instructions.

Monitoring

Monitor the application site for graft take, haemostasis and any hypersensitivity reaction.

Counselling the patient

  • This biological glue helps hold the graft in place and reduce bleeding.
  • It is absorbed by the body as the wound heals.
  • Report any rash, swelling or breathing difficulty after the procedure.

Evidence & guidelines

Fibrin sealants are well established for graft fixation and haemostasis in burns and reconstructive surgery, with labelling warning against intravascular use.

Reference: MHRA Drug Safety Update 2009 (air embolism); Tisseel/Artiss SPC; Currie et al. Burns 2013 (fibrin glue in STSG); NICE Interventional Procedures Guidance IPG537; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.